Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Journal of Clinical Oncology, Vol 24, No 22 (August 1), 2006: pp. 3657-3663
© 2006 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2006.06.1044

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kudoh, S.
Right arrow Articles by Fukuoka, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kudoh, S.
Right arrow Articles by Fukuoka, M.
Related Articles
Right arrowRelated Correspondence

Phase III Study of Docetaxel Compared With Vinorelbine in Elderly Patients With Advanced Non–Small-Cell Lung Cancer: Results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904)

Shinzoh Kudoh, Koji Takeda, Kazuhiko Nakagawa, Minoru Takada, Nobuyuki Katakami, Kaoru Matsui, Tetsu Shinkai, Toshiyuki Sawa, Isao Goto, Hiroshi Semba, Takashi Seto, Masahiko Ando, Taroh Satoh, Naruo Yoshimura, Shunichi Negoro, Masahiro Fukuoka

From the Department of Respiratory Medicine, Osaka City University Medical School; Department of Medical Oncology, Osaka City General Hospital; Department of Medical Oncology, Kinki University Medical School; Department of Respiratory Medicine, Rinku General Medical Center; Department of Thoracic Malignancy, Osaka Prefectural Medical Center for Respiratory and Allergic Diseases; Department of Respiratory Medicine, Osaka Medical College, Osaka; Division of Respiratory Medicine, Kobe City General Hospital, Kobe; Department of Internal Medicine, Shikoku Cancer Center, Ehime; Department of Respiratory Medicine, Gifu Municipal Hospital, Gifu; Department of Internal Medicine, Kumamoto Regional Medical Center, Kumamoto; and the Health Service, Kyoto University, Kyoto, Japan

Address reprint requests to Shinzoh Kudoh, MD, Department of Respiratory Medicine, Osaka City University Medical School, 1-4-3, Asahimachi, Abeno-ku, Osaka 545-8585, Japan; e-mail: shinzohykudoh{at}med.osaka-cu.ac.jp

PURPOSE: Docetaxel has shown activity in elderly patients with advanced non–small-cell lung cancer (NSCLC). This randomized phase III trial evaluated the efficacy and safety of docetaxel versus vinorelbine (the current standard treatment) in elderly patients.

PATIENTS AND METHODS: Chemotherapy-naïve patients age 70 years or older with stage IIIB/IV NSCLC and performance status 2 or lower were eligible. Patients randomly received docetaxel 60 mg/m2 (day 1) or vinorelbine 25 mg/m2 (days 1 and 8) every 21 days for four cycles. The primary end point was overall survival. Overall disease-related symptom improvement was assessed using an eight-item questionnaire.

RESULTS: In total, 182 patients were enrolled. Median age was 76 years (range, 70 years to 86 years). There was no statistical difference in median overall survival with docetaxel versus vinorelbine (14.3 months v 9.9 months; hazard ratio, 0.780; 95% CI, 0.561 to 1.085; P = .138). There was a significant difference in median progression-free survival (5.5 months v 3.1 months; P < .001). Response rates were also significantly improved with docetaxel versus vinorelbine (22.7% v 9.9%; P = .019). The most common grade 3 to 4 toxicities were neutropenia (82.9% for docetaxel; 69.2% for vinorelbine; P = .031) and leukopenia (58.0% for docetaxel; 51.7% for vinorelbine). Other toxicities were mild and generally well tolerated. Docetaxel improved overall disease-related symptoms over vinorelbine (odds ratio, 1.86; 95% CI, 1.09 to 3.20).

CONCLUSION: Docetaxel improved progression-free survival, response rate, and disease-related symptoms versus vinorelbine. Overall survival was not statistically significantly improved at this time. Docetaxel monotherapy may be considered as an option in the standard treatment of elderly patients with advanced NSCLC.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.


Related Correspondence

  • Docetaxel As Monotherapy in the Treatment of Advanced Non–Small-Cell Lung Cancer in Elderly Patients
    Ashok K. Malani, Rony M. Abou-Jawde, Jaswinder Singh, and Sarah A. Taylor
    JCO 2007 25: 1143-1144 [Full Text]
  • Single-Agent Chemotherapy for the Treatment of Elderly Patients With Advanced Non–Small-Cell Lung Cancer: What Is the Best Drug?
    Cesare Gridelli, Paolo Maione, and Antonio Rossi
    JCO 2007 25: 1444-1445 [Full Text]


This article has been cited by other articles:


Home page
JCOHome page
R. Maruyama, Y. Nishiwaki, T. Tamura, N. Yamamoto, M. Tsuboi, K. Nakagawa, T. Shinkai, S. Negoro, F. Imamura, K. Eguchi, et al.
Phase III Study, V-15-32, of Gefitinib Versus Docetaxel in Previously Treated Japanese Patients With Non-Small-Cell Lung Cancer
J. Clin. Oncol., September 10, 2008; 26(26): 4244 - 4252.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
S. Kudoh, H. Kato, Y. Nishiwaki, M. Fukuoka, K. Nakata, Y. Ichinose, M. Tsuboi, S. Yokota, K. Nakagawa, M. Suga, et al.
Interstitial Lung Disease in Japanese Patients with Lung Cancer: A Cohort and Nested Case-Control Study
Am. J. Respir. Crit. Care Med., June 15, 2008; 177(12): 1348 - 1357.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
T. K. Owonikoko, C. C. Ragin, C. P. Belani, A. B. Oton, W. E. Gooding, E. Taioli, and S. S. Ramalingam
Lung Cancer in Elderly Patients: An Analysis of the Surveillance, Epidemiology, and End Results Database
J. Clin. Oncol., December 10, 2007; 25(35): 5570 - 5577.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
C. Gridelli, C. Langer, P. Maione, A. Rossi, and S. E. Schild
Lung Cancer in the Elderly
J. Clin. Oncol., May 10, 2007; 25(14): 1898 - 1907.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
S. Kudoh
In Reply
J. Clin. Oncol., April 10, 2007; 25(11): 1446 - 1446.
[Full Text] [PDF]


Home page
JCOHome page
C. Gridelli, P. Maione, and A. Rossi
Single-Agent Chemotherapy for the Treatment of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: What Is the Best Drug?
J. Clin. Oncol., April 10, 2007; 25(11): 1444 - 1445.
[Full Text] [PDF]


Home page
JCOHome page
A. K. Malani, R. M. Abou-Jawde, J. Singh, and S. A. Taylor
Docetaxel As Monotherapy in the Treatment of Advanced Non-Small-Cell Lung Cancer in Elderly Patients
J. Clin. Oncol., March 20, 2007; 25(9): 1143 - 1144.
[Full Text] [PDF]


Home page
JCOHome page
S. Kudoh
In Reply
J. Clin. Oncol., March 20, 2007; 25(9): 1144 - 1144.
[Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2006 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online